Document:

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Exhibit 10.18  

EPO RECEPTOR LICENSE AGREEMENT  

        THIS AGREEMENT, effective this 5 day of September, 1996, between GENETICS INSTITUTE, INC., a corporation of the State of Delaware, with its principle place
of business at 87 CambridgePark Drive, Cambridge, Massachusetts, 02140, hereinafter referred to at "GI" and the licensee set out on the signature page below, hereinafter referred to as "LICENSEE", 

WITNESSETH
THAT: 

        WHEREAS,
GI represents that it is the assignee and/or exclusive licensee of, and has full right to sublicense Licensed Patent Rights as defined below, and 

        WHEREAS,
LICENSEE wishes to obtain a non-exclusive license under said Licensed Patent Rights in order to utilize materials and/or processes covered by Licensed Patent Rights
in its research and development activities, 

        NOW
THEREFORE, the parties agree as follows: 

ARTICLE I—DEFINITIONS  

	A.
	"Licensed
Patent Rights" means U.S. 5,278,065 and U.S. 5,378,808 as well as any or all reissue(s) thereof.

	B.
	"Effective
Date" means the date indicated above as the effective date of this Agreement.

	C.
	"Affiliate"
means any corporation, company, partnership, joint venture and/or firm which controls, is controlled by or is under common control with a party hereto. For purposes of this
definition, "control" shall mean (a) in the case of corporate entities, direct or indirect ownership of at least 50% of the securities of the corporation; and (b) in the case of
non-corporate entities, direct or indirect ownership of at least 50% of the equity 

1

 

interest
in such entity or possession of at least 50% of the power to direct the management and policies of such non-corporate entities. 

	D.
	"Selling
Price" means the gross sales price for that quantity of product subject to fee hereunder billed by LICENSEE or an Affiliate to third parties, less (i) cash and trade
discounts and credits for returns and allowances; (ii) sales or other excise taxes or duties imposed upon and paid by LICENSEE or an Affiliate; and (iii) selling commissions paid by
LICENSEE or an Affiliate.

	E.
	"Licensed
Product" means a product identified as a commercial candidate directly or indirectly utilizing any material and/or process covered by Licensed Patent Rights, as well as any
derivative of such product.

	F.
	"Field"
means research and development utilizing materials and/or processes covered by Licensed Patent Rights; the Field shall not include the selling of products covered by Licensed
Patent Rights. 

ARTICLE II—PATENT LICENSE  

        As of the date of receipt by GI of the sum of [*] U.S. dollars
([*]) pursuant to Article III-A, GI hereby grants to LICENSEE and its Affiliates a non-exclusive
license under the Licensed Patent Rights in the Field. 

ARTICLE III—PAYMENTS AND REPORTS  

	A.
	Within
thirty (30) days after the Effective Date of this Agreement LICENSEE shall pay to GI [*] U.S.
dollars ([*]) which shall not be returnable in any event but shall constitute an advance payment to be applied against running
fees owing to GI under paragraph B of this Article III.

	B.
	LICENSEE
shall pay to GI running fees which shall not be returnable in any event at the rate of [*] of the
Selling Price of all quantities of Licensed Product sold by LICENSEE and each Affiliate. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

2

 
	C.
	LICENSEE
shall pay to GI [*] U.S. dollars
($[*]) upon the start of [*] of each Licensed Product,
and an additional [*] U. S dollars ([*]) upon the  [*] (or equivalent) [*]
 for each Licensed Product.

	D.
	In
the event that any quantity of the Licensed Product is sold by LICENSEE to an Affiliate, only one fee shall be paid to GI (in order that duplication of fees be avoided) and that fee
shall only be paid when Affiliate has sold the said quantity of the Licensed Product to a third party which is not an Affiliate of the Licensee.

	E.
	Until
such time as LICENSEE and Affiliate have sold all quantities of the Licensed Product, LICENSEE shall report in writing to GI within sixty (60) days after the end of each
calendar quarter beginning with the first sale of the Licensed Product, the quantities of Licensed Product that were sold by LICENSEE and Affiliate during said quarter and the calculation of fees
thereon. With said report LICENSEE shall pay to GI the total amount of the said fees that have not been paid in advance. Reports, notices and other communications to LICENSEE hereunder shall be sent
to: 

Legal
Department

Affymax Research Institute

4001 Miranda Avenue

Palo Alto, CA 94304

        and
to GI shall be sent to: 

GENETICS
INSTITUTE, INC.

87 CambridgePark Drive

Cambridge, Massachusetts 02140

Attn: Legal Department 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

3

 
ARTICLE IV—RECORDS  

        LICENSEE shall keep, and require each Affiliate to keep, adequate records in sufficient detail to enable the fees due hereunder to be determined, and permit said
records to be inspected at any time during regular business hours, but not more than once annually, by an independent auditor, appointed and paid by GI for this purpose and not unacceptable to
LICENSEE, who shall report to GI only the amount of the royalties due hereunder. Nothing herein shall require LICENSEE or any Affiliate to retain such records longer that three (3) years after
the fees to which they relate are paid. 

ARTICLE V—TERMINATION  

	A.
	This
Agreement unless earlier terminated as hereinafter provided shall terminate with the last to expire of the Licensed Patent Rights.

	B.
	In
the event that any stipulation or provision of this Agreement is breached by LICENSEE or an Affiliate, GI, upon (60) days' advance written notice, may terminate this
Agreement and all rights granted hereunder. However, if such a breach is corrected within the sixty (60)-day period, this Agreement and the rights granted shall continue in force.

	C.
	Termination
of this Agreement shall not relieve LICENSEE or any Affiliate of any obligation hereunder to keep records, nor shall such termination relieve any obligations to make
payment of any sum due pursuant to Article III, or provide written reports with respect thereto. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

4

 
ARTICLE VI—INDEMNIFICATION  

        LICENSEE shall defend, indemnify and hold harmless GI and its Affiliates and their officers, directors and employees for any claim made for death, personal
injury, illness, property damage, intellectual property infringement, contract or other claim, or other injury or damage arising out of the actions hereunder of LICENSEE and its Affiliates hereunder
and their customers. 

ARTICLE VII—ASSIGNABILITY  

        Neither this Agreement nor the rights herein granted may be assigned by either party to any third party without the written consent of the other, which consent
shall not be unreasonably withheld; provided, however, this Agreement and the rights may be assigned by a party, without such written consent, to the successor of its entire business relating to the
subject matter of this Agreement. 

ARTICLE VIII—APPLICABLE LAW  

        This Agreement is acknowledged to have been made in and shall be construed in accordance with the laws of the State of Delaware. 

ARTICLE IX—MEDIATION  

        Any dispute between the parties that arises in connection with this Agreement will be resolved by mediation. Either party shall have the right to submit a
disputed issue to mediation by notifying the other party in writing. Within thirty (30) days of such notice, the parties shall exchange position papers setting forth the terms and conditions
each would accept as a resolution of the dispute and, based on the position papers, attempt in good faith to settle the dispute. If 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

5

 

the
parties are unable to settle the dispute within sixty (60) days of such notice, the parties shall agree on an independent mediator. If the parties are unable to agree on a single mediator,
each party will name an independent mediator within ninety (90) days after such notice and the two named mediators will in turn name a third independent mediator within one hundred twenty
(120) days after such notice. Statements by the parties supporting their respective positions will be filed with the mediator(s) within thirty (30) days after the parties agree on a
single mediator or thirty (30) days after three mediators are named. The mediator(s) will issue a written decision within sixty (60) days thereafter setting the terms and conditions for
the resolution of the dispute. The mediator(s) will not be bound by the positions of the parties and may set terms and conditions which are deemed fair, equitable and consistent with industry practice
in comparable cases. Either party may request an oral hearing upon filing its statement which will take place at the direction of the mediator(s) within thirty (30) days thereafter. The parties
shall be bound by the decision of the mediators(s). 

        IN WITNESS WHEREOF, the parties have executed this Agreement and have entered the effective date on the first page hereof. 

	 	 	GENETICS INSTITUTE, INC.
	

 	
 	

By:	

/s/  THOMAS J. DESROSIER      
 Name: Thomas J. DesRosier

Title: Vice President and Chief Patent Counsel
	

 	
 	

AFFYMAX RESEARCH INSTITUTE
	

 	
 	

By:	

/s/  GORDON RINGOLD      
 Name: Gordon Ringold

Title: CEO

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

6[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Exhibit 10.19

LICENSE AGREEMENT
  (THERAPEUTIC PRODUCTS) 

        THIS
LICENSE AGREEMENT (this "Agreement"), effective as of June 28, 1996 (the "Effective Date"), is by and among DYAX CORP., a
Delaware corporation, and PROTEIN ENGINEERING CORPORATION, a Massachusetts corporation and wholly-owned subsidiary of Dyax Corp., each having a
principal place of business at 765 Concord Avenue, Cambridge, Massachusetts 02138 (collectively referred to herein as "Licensor"); and AFFYMAX TECHNOLOGIES,
N.V. ("Licensee"), having a registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 ONN, England. 

RECITALS  

        A.    Licensor
has the right to grant licenses to and under certain technology described and claimed in U.S. Patent No. 5,223,409 entitled "Directed Evolution of Novel Binding
Proteins", U.S. Patent No. 5,403,484 entitled "Viruses Expressing Chimeric Binding Proteins", and associated patent rights. 

        B.    Licensee
desires to obtain a license from Licensor to practice the inventions described in the patents referenced above and Licensor is willing to grant such a license on
the terms and subject to the conditions provided herein. 

        NOW,
THEREFORE, in consideration of the mutual covenants set forth in this Agreement, the parties hereby agree as follows: 

ARTICLE 1.

DEFINITIONS  

        For purposes of this Agreement, the terms defined in this Article shall have the meanings specified below: 

        1.1.  "Affiliate" shall mean a corporation or other legal entity that controls, is controlled by, or is under common control
with such party. For purposes of this definition, "control" means the ownership, directly or indirectly, of more than fifty percent (50%) of the outstanding equity securities of a corporation which
are entitled to vote in the election of directors or a more than fifty percent (50%) interest in the net assets or profits of an entity which is not a corporation. Notwithstanding anything in this
definition to the contrary, Nippon Glaxo Limited, Shinjuku MAYNDS Tower, 1-1, Yoyogi 2-chrome, Shubuya-ku 151, Tokyo, Japan, and Maxygen, Inc. (presently a
division of Licensee), 40001 Miranda Avenue, Palo Alto, CA 94304 shall be deemed to be an Affiliate of Licensee for purposes of this Agreement. 

        1.2.  "Field of Use" shall mean human therapeutic products only and not any other produce purposes such as any  in vitro or in vivo diagnostics, imaging, purification or separations, research products, industrial
enzymes, or for any other uses or purposes. 

1

 

        1.3.  "Licensed Intermediate" shall mean any fusion protein (including without limitation any chimeric binding protein),
genetic package (including without limitation any virus, spore or cell) or other intermediate compound, or any compound derived from any of the foregoing, that is (i) discovered, made or
developed by Licensee using a method covered in whole or in part by Patent Rights or (ii) is otherwise covered by Patent Rights. 

        1.4.  "Licensed Product" shall mean any product intended for sale to an End User as a human therapeutic that prior to or after
the effective date is (i) discovered, made or developed by Licensee or its Affiliates using a Licensed Intermediate or a method covered in whole or in part by Patent Rights or
(ii) otherwise covered by Patent Rights. 

        1.5.  "Patent Rights" shall mean all Valid Claims (defined below) of United States Patent Nos. 5,223,409 and 5,403,484,
reissues, reexaminations, renewals and extensions thereof, and all continuations, continuations-in-part and divisionals of the applications for such patents, in the United
States and all counterparts thereto in countries outside the United States, all of which patents and patent applications as of the Effective Date are listed in Attachment
A. Patent Rights shall not include Valid Claims that are limited to compounds that bind to a specific biological or molecular target nor Valid Claims in U.S. Patent
No. 5,233,409 to the extent they cover single chain antibodies. 

        1.6.  "Valid Claim" shall mean either (a) a claim of an issued patent that has not been held unenforceable or invalid
by an agency or a court of competent jurisdiction in any unappealable or unappealed decision or (b) a claim of a pending patent application that has not been abandoned or finally rejected
without the possibility of appeal or refiling. 

        The
above definitions are intended to encompass the defined terms in both the singular and plural forms. 

ARTICLE 2.

GRANT OF RIGHTS & MUTUAL RELEASE  

        2.1.    License Grant.    Subject to the terms and conditions set forth herein, Licensor hereby grants Licensee and
its Affiliates a world-wide, nonexclusive license (without the right to grant sublicenses) under Patent Rights to make, have made, use, sell and have sold Licensed Products in the Field of
Use. 

        2.2.    Limitation of Rights.    Licensee acknowledges that its rights under Patent Rights are limited to those
expressly granted herein and that Licensee is expressly prohibited from selling, transferring or otherwise making available to third parties (i) Licensed Intermediates, and (ii) Licensed
Products for use outside the Field of Use; provided however, that Licensee shall not be prohibited from making such materials available to academic collaborators for non-commercial
research purposes. 

        2.3.    Covenant Not to Sue.    In partial consideration for the grant of rights hereunder, Licensee agrees not to
enforce against Licensor or its Affiliates any patent right owned or controlled by Licensee or its Affiliates during the term of this Agreement that Licensor or its Affiliates may infringe in
practicing the inventions claimed in Patent Rights, including the patent rights listed in Attachment B. Nothing in this Section 2.3 is intended
to grant Licensor or its Affiliates any proprietary rights or rights to nonsuit with respect to specific peptides, proteins, antibodies or analogs thereof. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

2

 

        2.4.    Mutual Release.    Licensor hereby agrees to unconditionally discharge and release Licensee and its
Affiliates, directors, officers, stockholders and employees (collectively, the "Licensee-Releasees") from any and all claims Licensor may have against the Releasees, and Licensee hereby agrees to
unconditionally discharge and release Licensor and its Affiliates, directors, officers, stockholders and employees (collectively, "Licensor-Releasees"), each with respect to any prior negotiations or
agreements relating to the Patent Rights between any Licensee-Releasee and Licensor-Releasee, including without limitation the Option Agreement effective as of January 9, 1995 between Protein
Engineering Corporation and Affymax Technologies N.V. 

ARTICLE 3.

PAYMENTS  

        3.1.    Payment Option Selection.    As consideration for the rights granted hereunder, Licensee agrees to pay to
Licensor by wire transfer the sum of [ * ] U.S. Dollars  [ * ]
by the Effective Date. 

ARTICLE 4.

REPRESENTATIONS AND WARRANTIES  

        4.1.    Authorization.    Each party represents and warrants to the other that it has the legal right and power to
enter into this Agreement, to extend the rights and licenses granted to the other in this Agreement, and to fully perform its obligations hereunder, and that the performance of such obligations will
not conflict with its charter documents or any agreements, contracts, or other arrangements to which it is a party. 

        4.2.    Ownership of Patent Rights.    Licensor represents and warrants that, as of the Effective Date, it possesses
the exclusive right, title, and interest in and to the Patent Rights and that it has the full legal right and power to enter into the obligations and grant the rights and licenses set forth in this
Agreement. 

        4.3.    Disclaimer of Warranties.    Nothing in this Agreement shall be construed as: 

        a.     a
warranty or representation by Licensor as to the validity or scope of any patent included within the Patent Rights; 

        b.     a
warranty or representation that the exploitation of the Patent Rights or the manufacture, use or sale of a Licensed Intermediate or a Licensed Products is or will be
free from infringement of patents of third parties; 

        c.     an
obligation of either party to bring or prosecute actions or suits against third parties for infringement; 

        d.     an
obligation of Licensor, other than to use its reasonable efforts, to maintain any patent or to continue to prosecute any patent application included within the Patent
Rights in any country; 

        e.     an
obligation of either party to furnish any confidential information or know-how; 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

3

 

        f.      creating
any agency, partnership, joint venture or similar relationship between Licensor and Licensee; or 

        g.     conferring
by implication, estoppel or otherwise any license, immunity or right under any patent of Licensor other than those specified in Patent Rights. 

ARTICLE 5.

INDEMNIFICATION  

        5.1.    Indemnification.    Licensee shall indemnify, defend, and hold harmless Licensor and its Affiliates and their
directors, officers, employees, and agents and their respective successors, heirs and assigns (the "Indemnities") against any liability, damage, loss, or expense (including reasonable attorneys fees
and expenses of litigation) incurred by or imposed upon the Indemnitees or any one of them in connection with any claims, suits, actions, demands, or judgments concerning any product, process or
service that is made, used, sold or provided pursuant to any right or license granted under this Agreement. 

ARTICLE 6.

TERM AND TERMINATION  

        6.1.    Term.    Unless sooner terminated as provided herein, this Agreement shall commence on the Effective Date and
shall remain in effect until the expiration of the last to expire of the applicable Patent Right, unless earlier terminated as provided in this Article. 

        6.2.    Termination by Licensor.    In the event that Licensee fails to make timely payment of the amount due to
Licensor under this Agreement, Licensor may terminate this Agreement upon ten (10) days written notice to Licensee, unless Licensee pays all past-due amounts prior to the expiration
of such ten (10)-day notice period. 

        6.3.    Other Material Breach.    In the event that either party commits a material breach of any of its obligations
under this Agreement and such party fails to remedy that breach within ninety (90) days after receiving written notice thereof from the other party, that other party may immediately terminate
this Agreement upon written notice to the breaching party. 

        6.4.    Effect of Termination.    Upon the expiration or termination of this Agreement, Licensee's rights under the
Patent Rights shall terminate immediately. Article 5 shall survive the expiration or termination of this Agreement. 

ARTICLE 7.

MISCELLANEOUS  

        7.1.    Governing Law.    This Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts. 

        7.2.    Consent to Jurisdiction.    The parties hereby irrevocably consent and submit to the exclusive jurisdiction of
any Commonwealth of Massachusetts or Federal court sitting in Boston in any action or proceeding of any type whatsoever arising out of or relating to this Agreement. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

4

 

        7.3.    Counterparts.    This Agreement may be executed in one or more counterparts, each of which shall be deemed an
original, and all of which together shall be deemed to be one and the same instrument. 

        7.4.    Headings.    All headings in this Agreement are for convenience only and shall not affect the meaning of any
provision hereof. 

        7.5.    Binding Effect.    This Agreement shall inure to the benefit of and be binding upon the parties and their
respective lawful successors and assigns. 

        7.6.    Assignment.    This Agreement may not be assigned by either party without the prior written consent of the
other party, except that either party may assign this Agreement to any of its Affiliates or to a successor in connection with the merger, consolidation, or sale of all or substantially all of its
assets or that portion of its business pertaining to the subject matter of this Agreement, with prompt written notice to the other party of any such assignment. 

        7.7.    Compliance With Law.    Nothing in this Agreement shall be construed so as to require the commission of any
act contrary to law, and wherever there is any conflict between any provision of this Agreement and any statute, law, ordinance or treaty, the latter shall prevail, but in such event the affected
provisions of the Agreement shall be conformed and limited only to the extent necessary to bring it within the applicable legal requirements. 

        7.8.    Notices.    All notices, requests, demands and other communications required or permitted to be given pursuant
to this Agreement shall be in writing and shall be deemed to have been duly given upon the date of receipt if delivered by hand, recognized international overnight courier, confirmed facsimile
transmission, or registered or certified mail, return receipt requested, postage prepaid to the following addresses or facsimile numbers:  

	If to Licensor:

Dyax Corp.

Protein Engineering Corporation

765 Concord Avenue

Cambridge, MA 02138

Attention: Chief Executive Officer

Facsimile: (617) 868-0898	 	If to Licensee:

To the address or facsimile

number set forth below

Licensee's signature to this

Agreement

        Either
party may change its designated address and facsimile number by notice to the other party in the manner provided in this Section. 

        7.9.    Amendment and Waiver.    This Agreement may be amended, supplemented, or otherwise modified only by means of a
written instrument signed by both parties. Any waiver of any rights or failure to act in a specific instance shall relate only to such instance and shall not be construed as an agreement to waive any
rights or fail to act in any other instance, whether or not similar. 

        7.10.    Severability.    In the event that any provision of this Agreement shall, for any reason, be held to be
invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect any other provision hereof, and the parties shall negotiate in good faith to modify the Agreement to
preserve (to the extent possible) their original intent. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

5

 

        7.11.    Entire Agreement.    This Agreement constitutes the entire agreement between the parties with respect to the
subject matter hereof and supersedes all prior agreements or understandings between the parties relating to the subject matter hereof. 

        IN
WITNESS WHEREOF, the undersigned have duly executed and delivered this Agreement as a sealed instrument effective as of the date first above written. 

	LICENSOR:	 	LICENSEE:
	
 PROTEIN ENGINEERING CORPORATION	
 	

AFFYMAX TECHNOLOGIES N.V. and

GLAXO WELLCOME
	

By: /s/  L. E. CANNON      
 Name: L. Edward Cannon

Title: President	
 	

By: /s/  JAMES NIEDEL      
 Name: J. Niedel

Title: Exec Director R&D
	
 DYAX CORP.	
 	

Address of Licensee:
	

 	
 	

	

 	
 	

	

 	
 	

	 	 	Facsimile:
                                         
            
	

By: /s/  HENRY E. BLAIR      
 Name: Henry E. Blair

Title: Chairman and CEO	
 	

 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]